Barclays’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-42,500
Closed -$213K – 4863
2024
Q1
$213K Buy
42,500
+9,500
+29% +$64.4K ﹤0.01% 4087
2023
Q4
$297K Buy
+33,000
New +$272K ﹤0.01% 4213
2022
Q1
– Sell
-31,200
Closed -$714K – 4939
2021
Q4
$714K Buy
+31,200
New +$739K ﹤0.01% 3017
2020
Q1
– Sell
-9,900
Closed -$201K – 6127
2019
Q4
$201K Sell
9,900
-132,600
-93% -$1.22M ﹤0.01% 5023
2019
Q3
$761K Buy
+142,500
New +$862K ﹤0.01% 3900
2019
Q1
– Sell
-50,000
Closed -$341K – 6993
2018
Q4
$341K Hold
50,000
– – ﹤0.01% 4168
2018
Q3
$332K Buy
+50,000
New +$280K ﹤0.01% 4600

Other funds holding AUPH

Barclays's AUPH Position: Q3 2026 in Review

Barclays increased its Aurinia Pharmaceuticals (AUPH) stake by 119% in Q3 2026, buying an estimated $527K and bringing the position to 60,952 shares worth $987K. The position accounts for ﹤0.01% of the portfolio, ranked #3060.

Barclays first reported a position in AUPH in Q2 2017 and has held it in 35 quarters since. The position peaked at $13.2M in Q3 2021. 277 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • Barclays held 60,952 shares of Aurinia Pharmaceuticals worth $987K as of Q3 2026.
  • Barclays bought 33,060 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $527K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3060 holding.
  • Barclays first reported a position in Aurinia Pharmaceuticals in Q2 2017 and has held it in 35 quarters since.
  • Barclays's Aurinia Pharmaceuticals position peaked at $13.2M in Q3 2021.
  • 277 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.